DDD Partners LLC Has $27.31 Million Stock Holdings in InMode Ltd. (NASDAQ:INMD)

DDD Partners LLC grew its stake in shares of InMode Ltd. (NASDAQ:INMD - Free Report) by 24.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,228,162 shares of the healthcare company's stock after purchasing an additional 240,856 shares during the period. InMode comprises about 3.7% of DDD Partners LLC's holdings, making the stock its 7th biggest holding. DDD Partners LLC owned 1.48% of InMode worth $27,314,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. BlackRock Inc. increased its position in InMode by 223.8% in the 2nd quarter. BlackRock Inc. now owns 5,443,513 shares of the healthcare company's stock worth $203,315,000 after purchasing an additional 3,762,511 shares during the last quarter. LSV Asset Management grew its position in InMode by 3,557.6% during the 3rd quarter. LSV Asset Management now owns 1,678,819 shares of the healthcare company's stock worth $51,137,000 after acquiring an additional 1,632,919 shares during the last quarter. State Street Corp grew its holdings in InMode by 199.1% during the 2nd quarter. State Street Corp now owns 1,736,843 shares of the healthcare company's stock worth $64,871,000 after acquiring an additional 1,156,213 shares during the last quarter. Millennium Management LLC raised its position in shares of InMode by 78.2% during the fourth quarter. Millennium Management LLC now owns 1,916,711 shares of the healthcare company's stock worth $68,427,000 after acquiring an additional 840,821 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in InMode by 607.6% during the second quarter. Geode Capital Management LLC now owns 862,587 shares of the healthcare company's stock worth $32,218,000 after buying an additional 740,690 shares during the last quarter. Institutional investors and hedge funds own 68.04% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. UBS Group raised their price objective on shares of InMode from $24.00 to $26.00 and gave the stock a "neutral" rating in a report on Wednesday, February 14th. Barclays boosted their price target on InMode from $32.00 to $34.00 and gave the company an "overweight" rating in a report on Thursday, February 15th. Finally, Canaccord Genuity Group reissued a "hold" rating and issued a $22.00 target price on shares of InMode in a research report on Thursday, December 7th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $33.00.

InMode Trading Up 1.9 %

InMode stock traded up $0.41 during trading hours on Thursday, reaching $21.61. 1,010,398 shares of the stock were exchanged, compared to its average volume of 1,567,525. The stock has a 50 day moving average of $22.58 and a two-hundred day moving average of $23.57. InMode Ltd. has a twelve month low of $18.57 and a twelve month high of $48.25. The company has a market cap of $1.81 billion, a P/E ratio of 9.40 and a beta of 2.17.

InMode (NASDAQ:INMD - Get Free Report) last released its quarterly earnings data on Tuesday, February 13th. The healthcare company reported $0.71 earnings per share for the quarter, beating the consensus estimate of $0.66 by $0.05. InMode had a return on equity of 29.80% and a net margin of 40.22%. The company had revenue of $126.80 million for the quarter, compared to the consensus estimate of $124.77 million. During the same quarter last year, the business posted $0.69 EPS. InMode's revenue for the quarter was down 5.1% on a year-over-year basis. On average, analysts expect that InMode Ltd. will post 2.24 earnings per share for the current fiscal year.

InMode Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.